Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon
Thumbnail

ACA plans likely to exclude top cancer hospitals

Coverage on the Affordable Care Act (ACA) insurance exchanges, where narrow network plans are dominant, is more likely to exclude doctors associated with National Cancer Institute (NCI)-designated cancer centers, according to a new study published in the Journal of Clinical Oncology.

Thumbnail

Senate unlikely to vote on ACA repeal until week of July 17

After failing to meet their self-imposed June 30 deadline to vote on the Better Care Reconciliation Act (BCRA), Senate Republicans now say they’ll need another week in Washington before the bill may advance.

Thumbnail

Value-based care doesn’t have to end independent practices

The transition to value-based care has led to consolidation and increased physician employment, but smaller practices may find a different option in pursuing alignments with other organizations which don’t involve giving up their independent status.

Two-thirds of patients haven’t completed advance directives for end-of-life care

Advance directives, like awarding power of attorney on health care decisions or completing a living will, haven’t been completed by most patients, including those with chronic illnesses, potentially complicating decisions by hospitals and physicians on end-of-life treatment.

Congress could stop IRS from enforcing individual mandate

Even if Republican-led efforts to repeal and replace the Affordable Care Act fail, the party’s members of Congress have a way to stop the Internal Revenue Service from enforcing one of the law’s most unpopular provisions: the individual mandate penalizing people who remain uninsured.

CMS: ACA reinsurance, risk adjustment ‘working as intended’

CMS’ internal review of the reinsurance and risk adjustment programs for the Affordable Care Act exchanges found the initiatives were succeeding stabilizing risk on the marketplace, going against claims of ACA opponents that the market has entered a “death spiral.”

Thumbnail

Providers won’t be able to avoid downside risk much longer

Among hundreds of healthcare finance professionals at a Healthcare Financial Management Association (HFMA) conference presentation, no one could say their systems were taking on downside risk above 5 percent of their total revenue. Francois de Brantes, MS, MBA, vice president and director of the Altarum Institute’s Center for Payment Innovation, said that needs to change.

Wasteful healthcare spending can’t be pinned on end-of-life care

Reducing medical spending in the last year of a patient’s life isn’t a panacea for limiting growth in overall healthcare costs, according to a study published in the July 2017 issue of Health Affairs.

Displaying 4473 - 4480 of 6649

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup